What are the most recent 5–10 authoritative guidelines on diffuse parenchymal lung disease and their publication dates?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Latest Authoritative Guidelines on Diffuse Parenchymal Lung Disease

The most recent authoritative guidelines specifically addressing diffuse parenchymal lung disease (DPLD) include the 2026 ACR Appropriateness Criteria® Diffuse Lung Disease update, the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, and the 2021 ACR Appropriateness Criteria® Diffuse Lung Disease.

Comprehensive List of Recent Guidelines (2021-2026)

Primary DPLD-Specific Guidelines:

  • ACR Appropriateness Criteria® Diffuse Lung Disease: 2026 Update 1

    • Published: 2026
    • Focus: Evidence-based imaging guidelines for suspected and confirmed diffuse lung disease, including initial evaluation, acute exacerbation assessment, and surveillance protocols
  • ATS/ERS/JRS/ALAT Clinical Practice Guideline: Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in Adults 2

    • Published: 2022 (American Journal of Respiratory and Critical Care Medicine)
    • Focus: Updated diagnostic criteria for IPF including transbronchial lung cryobiopsy (TBLC), UIP pattern recognition, and management of progressive fibrotic disease
  • ACR Appropriateness Criteria® Diffuse Lung Disease 3

    • Published: 2021
    • Focus: Imaging appropriateness for chronic dyspnea, inhalational exposures, and systemic diseases with lung involvement

Related Guidelines Addressing DPLD Components:

  • ERS/ATS Guidelines for Primary Ciliary Dyskinesia Diagnosis 4

    • Published: 2025
    • Focus: Unified diagnostic approach for ciliary dysfunction-related lung disease using GRADE methodology
  • Practical Guidance for CTD-Related Interstitial Lung Disease 5

    • Published: 2024
    • Focus: Early recognition and follow-up of connective tissue disease-associated ILD, including screening protocols for systemic sclerosis and rheumatoid arthritis
  • French Practical Guidelines: Diagnosis and Management of Idiopathic Pulmonary Fibrosis 6

    • Published: 2014
    • Focus: HRCT and histopathological UIP pattern criteria, exclusion of alternative diagnoses

Key Distinguishing Features

The 2026 ACR update 1 represents the most current imaging-focused guideline, establishing protocols for three distinct clinical scenarios: initial suspected disease, acute deterioration, and surveillance. This guideline employs RAND/UCLA Appropriateness Method and GRADE criteria for evidence evaluation.

The 2022 ATS/ERS/JRS/ALAT guideline 2 provides the most recent consensus on histopathological diagnosis, notably addressing the evolving role of TBLC as an alternative to surgical lung biopsy, with specific criteria for UIP and probable UIP patterns in multidisciplinary discussion contexts.

Important Context

The 2003 BTS guideline 7 on "diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults" is mentioned in the evidence but is now over 20 years old and has been superseded by more recent international consensus documents. The field has evolved substantially since then, particularly regarding imaging criteria, genetic testing, and antifibrotic therapies.

Note that several guidelines use overlapping terminology: diffuse lung disease (DLD), diffuse parenchymal lung disease (DPLD), and interstitial lung disease (ILD) are used interchangeably in modern literature 3, 1, 8, though "interstitial" is increasingly recognized as misleading since most pathologies involve alveolar and airway compartments beyond the interstitium.

Related Questions

In a 40-year-old woman with progressive dyspnea, a 20‑pack‑year smoking history, normal vital signs, diffuse thin‑walled cysts on chest CT including the costophrenic angles, a renal angiomyolipoma, negative serology for connective tissue disease, and a serum vascular endothelial growth factor‑D level of 1200 pg/mL, what is the most likely diagnosis?
What are the differential diagnoses for cystic lung disease in a female patient?
What is the differential diagnosis and recommended work‑up for an adult presenting with a diffuse patchy reticulonodular pattern on chest imaging of both lungs?
In an otherwise healthy 50-year-old man with a history of childhood thoracic surgery who incidentally has a large air‑filled cyst (bulla) in the right lower chest wall and is asymptomatic, should we manage it with watchful waiting or proceed with surgical removal?
What are the guideline recommendations for diagnosing and managing diffuse parenchymal lung disease, including idiopathic pulmonary fibrosis (IPF) and connective‑tissue‑disease‑associated interstitial lung disease (CTD‑ILD)?
What is the benign lipoma-like lesion that can occur in the calcaneal body?
What is the clinical significance of the tree‑in‑bud pattern on a chest computed tomography scan, what are the main differential diagnoses, and is this pattern commonly associated with aspiration?
What is the single most useful test to order to rule out Mycobacterium infection in a patient with a tree‑in‑bud pattern on imaging?
Can Cologuard (stool DNA test) yield a positive result in patients with ulcerative colitis?
What percentage of Cologuard (multi-target stool DNA test) positive results correspond to colorectal cancer?
What is the recommended approach to assess nutritional status in elderly patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.